Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion
Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member
PUBLICATIONS
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.COMMENTARY
Do Biologics Protect Against COVID-19 Infection?
In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers. These findings led the authors to conclude that patients with IMIDs on cytokine inhibitor therapies have reduced susceptibility to SARS-CoV2 infection compared with patients not receiving cytokine-inhibitors, as well as the general population.
While these findings are highly intriguing, they have to be taken with caution. Thus, while the findings described here are significant, they are based on very small sample sizes and lack validation from an independent cohort. Furthermore, using a survey to control for exposure is likely inadequate as it may not capture subtle changes in behavior that are not easily caught on survey questionnaires. In addition, while these treatments inhibit specific inflammatory pathways and may be protective against more severe COVID-192, it is hard to envision how they’d prevent seroconversion of exposed patients. This is supported by studies showing blunted, but not absent, vaccination responses to influenza vaccine3. Lastly, if the implications of this study hold true, it would also have potential implications regarding the utility of vaccinating patients for COVID while on biologics.
In summary, while these findings are intriguing, the message from this paper that patients with IMIDs on biologics are protected against COVID-19 infection has to be taken with great caution. More extensive and robust studies are required before we can confidently determine that biologics protect against SARS-CoV-2 infection.
Reference:
Categories
Tags
Recent Posts
IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives
Meet Our Newest Councilors
IPC and IFPA Joint Statement on Diversity and Inclusion
Also Read
Prioritizing the Patient Perspective in Psoriasis Care and Communications
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Revised IPC Statement on COVID-19
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Subscribe to the IPC Newsletter